Definitive Contract 75F40121C00180

Award Date 9/28/21
Potential Completion Date 3/27/24
Potential Value $426K
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct a study on the duration of pertussis immunity in baboons. The contract has a ceiling value of $171,069.00 and a period of performance ending on February 28, 2025. The contract does not have a set-aside designation. MD Anderson Cancer Center is a comprehensive cancer treatment and...
The Department of Health and Human Services Food and Drug Administration awarded a $143,340.00 firm fixed price purchase order to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct a one-year study on baboons that have recovered from Bordetella pertussis (whooping cough) infection. The study will assess the duration of immune responses to B. pertussis in the research animals. This award is not associated with any larger contract...
This is a firm fixed price purchase order issued by the Department of Health and Human Services Food and Drug Administration (FDA) to The University of Texas MD Anderson Cancer Center (MD Anderson), a component of the University of Texas System, to provide 24 age-matched, Bordetella-free weanling baboons for use in Pertussis infection and vaccination studies. The contract has a potential value of $187,360.62 and was awarded on April 19, 2019 under full and open competition, with no set-aside...
This is a $224,715.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is for a study titled "MERKELOMV-AP STUDY (BABOONS)" with a completion date of September 2, 2022. The contract does not have a set-aside designation. MD Anderson Cancer Center is a comprehensive cancer treatment and research...
The University of Texas MD Anderson Cancer Center has been awarded a firm fixed price contract valued at approximately $911,653 by the Department of Health and Human Services Food and Drug Administration to conduct a study evaluating the duration of pertussis immunity in baboons. The contractor will house and evaluate up to 24 vaccinated baboons and 12 convalescent baboons over a period of five years in accordance with the statement of work. Samples will be collected and vaccines administered to...
This is a prime contract awarded by the U.S. government to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is for $6,155,674.00 and is a Definitive Contract with Cost No Fee pricing. The place of performance is Texas, USA. The contract is for biomedical (applied/exploratory) services and does not have a set-aside designation. MD Anderson Cancer Center, a comprehensive cancer treatment and research center, has received this prime...
This federal contract was awarded by the Department of Health and Human Services' Food and Drug Administration to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $283,546.12, is for a study titled "Modular Application of Surface Technology for the Generation of Antigen-Specific T Cells." It is a definitive contract with a cost-no-fee pricing type, awarded on September 13, 2019 with a completion date of...
This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer...
This is a federal contract award from the Office of Logistics and Acquisition Operations, a component of the National Institutes of Health (NIH), to The University of Texas M.D. Anderson Cancer Center (MD Anderson). The contract, with a ceiling value of $171,500.00, is for the acquisition, testing, transportation, and housing of non-human primate research colonies to support infectious disease and immunology studies at NIH facilities. The contract is a delivery order under a larger indefinite...
This is a federal contract award to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for veterinary and animal care services. The $17,369,042.37 Definitive Contract has a period of performance ending on September 11, 2013 and was awarded on August 29, 2003 by the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH). The contract does not have a set-aside designation. As a...

This is a firm-fixed-price federal contract award valued at $425,645.08 from the Food and Drug Administration (FDA) to The University of Texas MD Anderson Cancer Center, a child entity of the University of Texas System. The contract is for an "IMMUNOGENICITY STUDY IN BABOONS FOLLOWING VACCINATION WITH EXPERIMENTAL ACELLULAR PERTUSSIS VACCINES" and does not have a set-aside designation.

MD Anderson, a leading academic cancer research and treatment institution, has extensive experience supporting federal agencies through contracts and grants. The University of Texas System, as the parent organization, also regularly secures federal awards across its various institutions for research, development, testing, and professional services. This contract award contributes to MD Anderson's expertise in conducting specialized non-human primate research, which is an important component of the FDA's mission to evaluate new vaccine candidates.

Generated 4/27/25, 12:51 AM